Results 141 to 150 of about 29,547 (250)

The Role of N6‐Methyladenosine Modification in Health and Disease

MedComm, Volume 7, Issue 6, June 2026.
N6‐methyladenosine (m6A) is the most prevalent internal RNA modification in eukaryotes, acting as a pivotal epitranscriptomic regulator of RNA metabolism. This modification plays a dual role: it maintains physiological homeostasis under normal conditions but drives disease progression when dysregulated.
Linghuan Li, Yuanhai Sun, Wanfang Zheng, Lingqin Li, Yaqian Feng, Minyou Qi, Hanbing Li   +6 more
wiley   +1 more source

Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma

[[abstract]]Claudins are key components of tight junctions, essential for maintaining cellular adhesion, regulating intercellular molecule transport, and preserving cell polarity.
Kuo, YH;Ong, KH;Sun, DP;Tian, YF;Chou, CL;Chan, TC;Hsing, CH;Li, WS;Li, CF;Shiue, YL
core   +1 more source

Metabolic Regulation of Immune Responses: Molecular Mechanisms, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 6, June 2026.
FBP1 loss drives immune evasion and therapy resistance by enhancing glycolysis, STAT3 activation, and PD‐L1 expression, leading to T cell exhaustion and NK cell inhibition. FBP1 restoration, via LNP‐mRNA or epigenetic modulation, reverses these immunosuppressive effects, reactivates cytotoxic T cells, promotes M1 macrophage polarization, and enhances ...
Chunwei Li, Ziqiang Liu, Dezheng Kong, Zhengze Li, Yiming Yan, Yanyu Dong, Lili Zhu, JiaNing Cao, Zhirui Fan, Gautam Sethi, Lifeng Li   +10 more
wiley   +1 more source

Hepatic Arterial Infusion Chemotherapy plus either Toripalimab or Sorafenib as First‐line Therapy for Locally Advanced Hepatocellular Carcinoma: A Non‐comparative, Randomized Phase 2 Trial

MedComm, Volume 7, Issue 6, June 2026.
This phase II study explored the efficacy and safety of HAIC plus toripalimab in locally advanced HCC. The primary endpoint was the PFS rate at 6 months. The 6‐month PFS rate was 63.9% in the TorHAIC group and 61.1% in the SoraHAIC group. Treatment with the TorHAIC regimen resulted in a median OS of 20.9 months and a median PFS of 9.1 months.
Zhicheng Lai, Aojie Ge, Hanyue Ouyang, Zichao Wu, Yexing Huang, Qijiong Li, Li Xu, Binkui Li, Minshan Chen, Dongsheng Wen, Anna Kan, Ming Shi, Minke He   +12 more
wiley   +1 more source

Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma

Nature Communications
Intratumoral immune status influences tumor therapeutic response, but it remains largely unclear how the status determines therapies for patients with intrahepatic cholangiocarcinoma.
Jia-Cheng Lu, Lei-Lei Wu, Yi-Ning Sun, Xiao-Yong Huang, Chao Gao, Xiao-Jun Guo, Hai-Ying Zeng, Xu-Dong Qu, Yi Chen, Dong Wu, Yan-Zi Pei, Xian-Long Meng, Yi-Min Zheng, Chen Liang, Peng-Fei Zhang, Jia-Bin Cai, Zhen-Bin Ding, Guo-Huan Yang, Ning Ren, Cheng Huang, Xiao-Ying Wang, Qiang Gao, Qi-Man Sun, Ying-Hong Shi, Shuang-Jian Qiu, Ai-Wu Ke, Guo-Ming Shi, Jian Zhou, Yi-Di Sun, Jia Fan   +29 more
doaj   +1 more source

Contemporary Analysis of VTE Risk After HPB Surgery: 2517 Consecutive Patients Treated With Extended Chemoprophylaxis

World Journal of Surgery, Volume 50, Issue 6, Page 1663-1665, June 2026.
Independent predictors of Venous Thromboembolism (VTE) within the first 45 post‐operative days on multivariate analyses.
Anish J. Jain, Esther N. Dekker, Laura Prakash, Elsa M. Arvide, Yi‐Ju Chiang, Rebecca A. Snyder, Matthew H. G. Katz, Ching‐Wei D. Tzeng   +7 more
wiley   +1 more source

Heterogeneity of Cancer‐Associated Fibroblasts and Precision Targeting Strategies for Cancer Therapy

Thoracic Cancer, Volume 17, Issue 11, June 2026.
CAFs orchestrate tumor immunosuppression through spatially organized ECM remodeling, cytokine signaling, and metabolic reprogramming. Targeting CAFs requires a shift from marker‐based depletion to functional state and niche‐specific intervention. ABSTRACT Immune checkpoint blockade (ICB) has transformed cancer therapy, but its effect is often limited ...
Yijie Wang, Guangyao Zhou, Pengpeng Zhang, Zhenfa Zhang, Lianmin Zhang   +4 more
wiley   +1 more source

Predictive Immunohistochemistry in Cholangiocarcinoma: Current Clinical Utility, Practical Limitations, and Emerging Directions

APMIS, Volume 134, Issue 6, June 2026.
ABSTRACT Cholangiocarcinoma (CCA) remains a difficult‐to‐treat biliary malignancy in which therapeutic stratification increasingly depends on predictive biomarkers. Although next‐generation sequencing is essential for the detection of targetable genomic alterations, immunohistochemistry (IHC) retains a practical role because it is widely available ...
Francesco Vasuri, Alessandra Boccaccino, Stefano Tamberi, Luca Saragoni   +3 more
wiley   +1 more source

A case report of primary intrahepatic adeno squamous cell cholangiocarcinoma

Introduction: Hepatocellular carcinoma is the most common form of primary liver cancer. Intrahepatic cholangiocarcinoma and fibrolamellar carcinoma make up most other cases.
Fionn Woulfe (19811338), Michael Devine (16489467), Adrian O'Sullivan (19811341), Rory Crotty (12509683), Brian Hayes (112164)   +4 more
core  

Cholangiocarcinoma in a central bearded dragon (Pogona vitticeps): A case report

Australian Veterinary Journal, Volume 104, Issue 6, Page 404-409, June 2026.
Cholangiocarcinoma is an uncommon malignant epithelial tumour of the biliary tract in reptiles and is rarely reported in central bearded dragons (Pogona vitticeps). This case report describes a 7‐year‐old male central bearded dragon in which a nonspecific coelomic opacity was incidentally detected during a routine clinical examination.
M Mikiewicz, K Paździor‐Czapula, I Otrocka‐Domagała   +2 more
wiley   +1 more source